Filing Overview
Elanco Animal Health Incorporated filed a Form 8-K dated October 30, 2018, reporting executive leadership and related compensation matters. The filing does not provide financial statements, operating results, cash flow, debt, liquidity, or period-specific guidance.
Material Event
- Todd S. Young was appointed Executive Vice President and Chief Financial Officer, effective November 1, 2018, and will serve as the company’s principal financial officer.
- Lucas Montarce will cease serving as Interim Chief Financial Officer, transition responsibilities to Mr. Young, and return to Eli Lilly & Company as vice president and CFO of Lilly’s International Business Unit.
Compensation Arrangements
- Annual base salary: $550,000.
- Annual cash incentive target: 70% of base salary.
- Annual equity award target: $1.2 million under the Elanco 2018 Stock Plan.
- One-time cash retention bonus: $200,000, earned over three years.
- One-time restricted stock unit award: $300,000, expected to be granted in December 2018 and vesting in equal installments on the first two anniversaries of the grant date.
- Relocation costs will be reimbursed, and Mr. Young will participate in customary executive benefit plans.
Management Commentary, Risks and Unusual Items
The filing describes Mr. Young’s prior executive roles at ACADIA Pharmaceuticals, Baxalta and Baxter International. It states that no material appointment-related arrangements existed with other persons, no applicable family relationships were identified, and no related-party transaction requiring disclosure under Item 404(a) was reported.
The compensation commitments represent incremental executive employment and retention obligations. The filing does not quantify the accounting expense, cash timing, or potential impact on future earnings or cash flow.
Key Facts to Verify
- Effective date of Mr. Young’s appointment: November 1, 2018.
- Whether the $200,000 retention bonus is ultimately earned over the full three-year period.
- Timing and terms of the expected $300,000 restricted stock unit grant.
- Actual annual equity awards and performance-based compensation paid in subsequent filings.
- Any financial statement effects, including compensation expense and cash payments, in subsequent periodic reports.
- The complete terms of the employment offer letter and Retention Bonus Agreement filed as Exhibits 10.1 and 10.2.